Physician profile
David Robert Draney
NPI 1891141644
$8,580.91
in general payments reported to CMS, 2019-2025
25 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $504 · 2021: $869 · 2022: $1,145 · 2023: $1,605 · 2024: $1,987 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,330 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,330.13 |
| Education | $106.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,469.08 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,041.79 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $763.89 | 2021-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $740.34 | 2020-2025 | Caplyta |
| Alkermes, INC. | $645.23 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $625.04 | 2020-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $531.48 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $262.76 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $262.43 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $226.51 | 2020-2023 | Trintellix |
| Tris Pharma INC | $199.50 | 2023-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $139.48 | 2020-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $130.09 | 2023-2025 | Auvelity |
| Shire North American Group INC | $87.11 | 2019 | |
| Eisai INC. | $76.64 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $70.57 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $64.41 | 2023-2024 | Jornay Pm |
| Sun Pharmaceutical Industries INC. | $58.02 | 2021 | |
| Avanir Pharmaceuticals, INC. | $48.18 | 2019 | |
| Sunovion Pharmaceuticals INC. | $44.25 | 2021-2022 | |
| Allergan, INC. | $30.75 | 2020 | |
| Corium, LLC | $22.69 | 2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $17.01 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $11.94 | 2019 | |
| Idorsia Pharmaceuticals US INC | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Draney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.